Immediately after surgery, the main pulmonary artery pressure was 30/10 mm Hg. A pulmonary angiogram prior to discharge revealed normal diameters of both pulmonary arteries.
Bilateral systolic murmurs remained audible but less intense than preoperation. The MRIon March 1985, three months postoperation, showed the main pulmonary artery and the left pulmonary artery to be of good caliber while the distal right pulmonary artery was slightly narrowed (Fig 2A and B) . Nine months after surgery, a repeat study showed progressive narrowing of the distal right pulmonary artery (Fig 2C) . One year after surgery, the MRI was unchanged. The patient has remained asymptomatic and had an uncomplicated pregnancy a year and a half after surgery. Takayasu's disease has been reported to be a cause of branch pulmonary artery stenosis, as well as pericarditis. This is usually in the context of more generalized disease involving the aortic branches, although cases of isolated pulmonary involvement may occur. 5 Our patient has no finding suggestive of aortic involvement by MRI. In addition, the pathology of the pulmonary artery in our patient does not resemble Takayasu's arteritis. Congenital causes of pulmonary artery stenosis 6 are easily eliminated here on the basis of the history and the pathologic findings. This patient represents a previously unreported cause of bilateral pulmonary artery stenosis.
Treatment of our patient involved unroofing and grafting the walls of the pulmonary arteries. Alternatively, a jump graft over the area of stenosis might have been used. Balloon angioplasty has been used in congenital varieties, but considering the rigidity of the vessels described at surgery, it is doubtful that it would have been successful in this case.
In the past, follow-up would have required repeat pulmonary angiography. This case shows the latest imaging technique (MRI) to be an effective, noninvasive method for following the progress of the lesions after surgery. Indeed, the initial diagnosis might have been established by MRI.
Hemodynamic aspects of pulmonary hypertension caused by bilateral branch pulmonary artery stenosis can also be evaluated noninvasively by echocardiographic and Doppler techniques. This patient will be followed in this fashion to augment the anatomic information obtained from the MRI.
In conclusion, this patient had bilateral pulmonary artery stenosis associated with pericarditis and inflammatory reaction. Postoperatively, MRI has been used effectively to follow the patients clinical course. A 21-year-old man was referred in 1985 for investigation of a heart murmur which had been diagnosed on routine examination. He was completely asymptomatic and gave no relevant past medical history. Examination revealed a continuous grade 2/6 murmur at the left fourth intercostal space. An electrocardiogram and a chest radiograph showed normal findings. Phonocardiography confirmed the auscultatory findings together with a continuous murmur of high frequency maximally in the xiphoid region. Two-dimensional echocardiography revealed a dilated vascular structure 1-1.5 cm in diameter along the left atrioventricular groove which corresponded to the circumflex artery (Fig 1) . On the inferior surface there was a more marked dilatation of this vessel at the normal site of the coronary sinus. Color Doppler showed a continuous turbulent flow pattern of high intensity maximally in the region of the coronary sinus. The cardiac chambers and valvular structures appeared normal. A diagnosis of coronary arteriovenous fistula (CAVF) between the circumflex artery and the coronary sinus was made. Nuclear magnetic resonance (NMR) showed a dilated vascular structure running along the left auriculoventricular sulcus. The myocardium appeared to be of uniform density and normal thickness (Fig 2) . The images were T weighed and obtained with a cardiac (Fig 3) . Contrast material was seen to flow to the right atrium. The pulmonary/systemic flow ratio was calculated at 1.8. The patient was advised to undergo surgical correction, which he refused.
DISCUSSION
Most patients with CAVF are completely asymptomatic and, some may develop complications such as bacterial endocarditis, ischemic heart disease or congestive heart FIGURE 2. NMR image shows a transverse slice at the base of the left ventricle. The dilated circumflex artery is well seen as a black structure. Note homogeneity of its thickness. CA-circumflex artery. failure. While surgery is strongly recommended for symptomatic patients and those with large shunts, the treatment of others is less clear since it is not known which subgroup will eventually become symptomatic. Our noninvasive investigations provided the diagnosis while cardiac catheterization further confirmed the diagnosis and measured the shunt size. The use of 2-DE and Doppler echocardiography in the diagnosis of CAVF has been discussed extensively in the literature. 29 Now, with the advent of color Doppler, the diagnosis can be made with greater certainty and in many cases the actual site of the fistula visualized. Nuclear magnetic resonance has a number of characteristics that are particularly well suited to the study of vessels. There is excellent contrast between flowing blood and cardiovascular structure without the need for injection of contrast medium. The images are of a very high quality throughout a large field and in any desired plane. Also, the absence of biologic effects allows serial examinations without risk to the patient. The availability of these new noninvasive imaging methods should provide useful information about the natural history of this abnormality and ultimately could help in the management and decision-making in young asymptomatic patients. 
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Safety enhanced by cardioselectivity
• Significantly less bronchospastic potential than propranolol 9 • Unique pharmacokinetics and titratability make relative cardioselectivity clinically useful
Blood pressure reduction
• In patients with SVT, significant decreases in blood pressure occurred in 20-50% of patients. About 12% of SVT patients experienced symptomatic hypotension (mainly dizziness and diaphoresis)-6% of total discontinued 
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INDICATIONS AND USAGE Supraventricular Tachycardia
BRFVIBLOC® (esmolol HCI
) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable BREVIBLOC® is also indicated in noncompensatory sinus tachycardia where, m the physician's judgement, the rapid heart rate requires specific intervention. BREVIBLOC® is not intended for use in chronic settings where transfer to another agent is anticipated.
CONTRAINDICATIONS
BREVIBLOC® (esmolol HCI) is contramdicated m patients with sinus bradycardia heart block greater than first degree, cardiogenic shock or overt heart failure (see Warnings)
WARNINGS
Hypotension:
In clinical trials 20-50% of patients treated with BREVIBLOC® (esmolol HCI) have had hypotension, generally defined as systolic pressure less than 90 mmHg and/or diastolic pressure less than 50 mmHg About 12% of the patients have been symptomatic (mainly diaphoresis or dizziness) Hypotension can occur at any dose but is dose-related so thai doses beyond 200 mcg/kg/mm are not recommended Patients should be closely monitored, especially if pretreatrnent blood pressure is low Decrease of dose or termination of infusion reverses hypotension, usually within 30 minutes Cardiac Failure: Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure Continued depression of the myocardium with beta blocking agents over a period of time can, in some cases, lead to cardiac failure At the first sign or symptom of impending cardiac failure, the dosage should be reduced or BREVIBLOC* should be withdrawn Although this dosage adjustment or withdrawal may be sufficient because of the short elimination halMife of BREVIBLOC®, specific treatment may also be considered (See Overdosage)
Bronchospastlc Diseases: PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA BLOCKERS. Because of its
relative betai selectivity and titratability, BREVIBLOC® may be used with caution in patients with bronchospastlc diseases However, since beta, selectivity is not absolute. BREVIBLOC® should be carefully titrated to obtain the lowest possible effective dose. In the event of bronchospasm, the infusion should be terminated immediately, a beta2 stimulating agent may be administered if conditions warrant but should be used with particular caution as patients already have rapid ventricular rates Diabetes Mellitus and Hypoglycemia: BREVIBLOC® should be used with caution in diabetic patients requiring a beta-blocking agent Beta blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected
PRECAUTIONS General
Infusion concentrations of 20 mg/mL were associated with more venous irritation and thrombophlebitis than concentrations of 10 mg/mL Concentrations greater than 10 mg/mL should, therefore, be avoided Because the acid metabolite of BREVIBLOC® is primarily excreted unchanged by the kidney, BREVIBLOC® (esmolol HCI) should be administered with caution to patients with impaired renal function The elimination half-life of the acid metabolite was prolonged ten told and the plasma level was considerably elevated in patients with end stage renal disease
Drug Interactions
Catecholamine depleting drugs, e g , reserpme. may have an additive effect when given with beta blocking agents Patients treated concurrently with BREVIBLOC® and a catecholamine depletor should therefore be closely observed for evidence ot hypotension or marked bradycardia which may result in vertigo, syncope, or postural hypotension A study of interaction between BREVIBLOC® and warfarin showed that concomitant administration of BREVIBLOC® and warfarin does not alter warfarin plasma levels BREVfBLOC® concentrations were equivocally higher when given with warfarin but this is not likely to be clinically important When digoxin and BREVIBLOC® (esmolol HCI) were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points Digoxin did not affect BREVIBLOC® pharmacokinetics When intravenous morphine and BREViBLOC® were concomitantly administered in normal subjects no effect on morphine blood levels was seen but BREVIBLOC® steady-state blood levels were increased by 46% in the presence of morphine No other pharmacokinetic parameters were changed The effect of BREVIBLOC* on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery The onset of neu romuscular blockade by succinylcholine was unaffected by BREVIBLOC®, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC® should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin
Carcinogenesis, Mutagenesis, Impairment of Fertility
Because of its short term usage no carcinogenicity mutagenicity or reproductive performance studies have been conducted with BREVIBLOC 5
Pregnancy Category C
Teratogenicity studies in rats at intravenous dosages of BREVIBLOC® up to 3000 mcg/kg/mm (ten times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/mm produced maternal toxicity and lethality In rabbits, intravenous dosages up to 1000 mcg/kg/mm for 30 minutes daily produced no evidence of maternal toxicity embryotoxicity or teratogenicity, while 2500 meg/ kg/mm produced minimal maternal toxicity and increased fetal resorptions There are no adequate and wetl controlled studies in pregnant women BREVIBLOC® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Nursing Mothers
It is not known whether BREVIBLOC® is excreted in human milk however caution should be exercised when BREVIBLOC® is administered to a nursing woman
Pediatric Use
The safety and effectiveness of BREVIBLOC* in children have not been established
ADVERSE REACTIONS Supraventricular Tachycardia
The following adverse reaction rates are based on use of BREVIBLOC® (esmolol HCI) m almost 400 clinical trial patients with supraventricular tachycardia In addition, over 600 patients have been exposed in clinical studies of other conditions The most important adverse effect has been hypotension (see Warnings) Most adverse effects have been mild and transient Cardiovascular--Symptomatic hypotension (diaphoresis, dizziness) occurred in 12% of patients, and therapy was discontinued in about 11%, about half of whom were symptomatic Asymptomatic hypotension occurred in about 25% of patients Hypotension resolved during BREVIBLOC® infusion in 63% of these patients and within 30 minutes after discontinuation of infusion in 80% of the remaining patients Diaphoresis accompanied hypotension in 10% of palients Peripheral ischemia occurred in approximately 1% of patients. Pallor, flushing, bradycardia (heart rate less than 50 beats per minute), chest pain, syncope, pulmonary edema and heart block have each been reported in less than 1% of patients In two patients without supraventricular tachycardia but with serious coronary artery disease (post inferior myocardial infarction or unstable angina), severe bradycardia/sinus pause/asystole has developed, reversible in both cases with discontinuation of treatment Central Nervous System-Dizziness has occurred in 3% of patients; somnolence in 3%. confusion, headache, and agitation in about 2%. and fatigue in about 1% of patients Paresthesia, asthenia, depression, abnormal thinking, anxiety, anorexia, and lightheadedness were reported in less than 1% of patients One brief (30 second) episode of grand mal seizure has been reported Respiratory-Bronchospasm, wheezing, dyspnea, nasal congestion, rhonchi, and lales have each been reported in less than 1% of patients Gastrointestinal-Nausea was reported in 7% of patients Vomiting has occurred in about 1% of patients Dyspepsia, constipation, dry mouth, and abdominal discomfort have each occurred in less than 1% of patients Taste perversion has also been reported Skin (Infusion Site) -Infusion site reactions including inflammation and induration were reported in about 8% of patients Edema, erythema, skin discoloration, and burning at the infusion site have each occurred in less than 1% of patients Miscellaneous Each of the following has been reported in less than 1% of patients Urinary retention, speech disorder, abnormal vision, midscapular pain rigors, and fever
OVERDOSAGE Acute Toxicity
A single case of accidental overdosage with BREVIBLOC® (esmolol HCI) has occurred to date A 5000 mcg/kg/mm dose of BREVIBLOC® instead of the recommended 500 mcg/kg/min loading dose was administered over one minute to a patient with atrial flutter Immediately following the infusion, marked decreases in heart rate and blood pressure were observed and the patient became drowsy but could be aroused The infusion rate of BREVIBLOC® was decreased to 5 mcg/kg/ mm and over the next eight minutes the patient's rhythm converted to normal sinus rhythm and the patient started feeling better. Hypotension persisted for a period of lour minutes after decreasing the dosage of BREVIBLOC®. The drowsiness disappeared 15 minutes following discontinuation of BREVIBLOC® Because of its approximately 9-minute elimination half-life, the first step in the event of toxicity should be to discontinue BREVIBLOC® administration Then, based on the pharmacologic actions, the following general measures should also be considered: Bradycardia: Intravenous administration of atropine or another anticholinergic drug Bronchospasm: Intravenous administration of a beta? stimulating agent and/or a theophylline derivative.
Cardiac Failure: Intravenous administration of a diuretic and/or digitalis glycoside. In shock resulting from inadequate cardiac contractility, intravenous administration of dopamine, dobutamine, isoproterenol, or amrinone may be considered
DOSAGE AND ADMINISTRATION
NOT FOR DIRECT INTRAVENOUS INJECTION BREVfBLOC® IS A CONCEN-TRATED, POTENT DRUG WHICH MUST BE DILUTED PRIOR TO ITS INFUSION. BREVIBLOC® SHOULD NOT BE ADMIXED WITH SODIUM BICARBONATE BREVIBLOC® SHOULD NOT BE MIXED WITH OTHER DRUGS PRIOR TO DILU-TION IN A SUITABLE INTRAVENOUS FLUID
Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit Dilution: Aseptically remove 20 mL from a 500-mL bottle of one of the intravenous fluids (refer to full prescribing information for compatibility with commonly used intravenous fluids) and add the contents of two (2) ampuls of BREVIBLOC® (each containing 2 5 g esmolol hydrochloride) This yields a final concentration of 10 mg/mL The diluted solution is stable for at least 24 hours at room temperature Note: Concentrations of BREVIBLOC® greater than 10 mg/mL are likely to produce irritation on continued infusion (see Precautions) BREVIBLOC® has, however, been well tolerated when administered via a central vein
Supraventricular Tachycardia
In the treatment of supraventricular tachycardia, responses to BREVIBLOC® usually (over 95%) occur within the range of 50 to 200 mcg/kg/mm The average effective dosage is approximately 100 mcg/kg/min although dosages as low as 25 mcg/kg/ mm have been adequate in some patients Dosages as high as 300 mcg/kg/min have been used, but these provide little added effect and an increased rate of adverse effects, and are not recommended Dosage of BREVIBLOC® in supraventricular tachycardia must be individualized by titration in which each step consists of a loading dosage followed by a maintenance dosage. To initiate treatment of a patient with supraventricular tachycardia, administer a loading dosage infusion of 500 mcg/kg/min of BREVIBLOC® for one minute followed by a 4 mm maintenance infusion of 50 mcg/kg/min If an adequate therapeutic effect is not observed within five minutes, repeat the same loading dosage and follow with a maintenance infusion increased lo 100 mcg/kg/min Continue titration procedure as above, repeating loading infusion (500 mcg/kg/min for 1 minute), increasing maintenance infusion by increments of 50 mcg/kg/min (for 4 minutes) As the desired heart rate or a safety end-point (eg . lowered blood pressure) is approached, omit the loading infusion and reduce incremental dose in maintenance infusion from 50 mcg/kg/min to 25 mcg/kg/min or lower Also, it desired, increase interval between titration steps from 5 to 10 minutes This specific dosage and administration regimen has not been studied intraoperative^ and because of the time required for titration, may not be optimal for intraoperative use Maintenance dosages above 200 mcg/kg/min have not been shown to have significantly increased benefits, and the safety of dosages above 300 mcg/kg/mm has not been studied In the event ot an adverse reaction, the dosage of BREVIBLOC® may be reduced or discontinued. If a local infusion site reaction develops, an alternative infusion site should be used. The use of butterfly needles should be avoided. Abrupt cessation of BREVIBLOC® in patients has not been reported to produce the withdrawal effects which may occur with abrupt withdrawal of beta-blockers follow mg chronic use in coronary artery disease (CAD) patients However, caution should still be used in abruptly discontinuing infusions of BREVIBLOC® in CAD patients After achieving an adequate control of the heart rate and a stable clinical status in patients with supraventricular tachycardia, transition to alternative antiarrhythmic agents such as propranolol, digoxin, or verapamil, may be accomplished A 31-year-old white man presented to a hospital emergency room in November, 1985 complaining of the acute onset of pain and pallor in the left leg from fhe mid-thigh to the foot. In 1982, he had been involved in a car accident during which he struck his chest forcefully on the windshield. Over the past two years he had had a number of similar but milder episodes of pain and pallor in the left arm and right foot. He was admitted and underwent emergency embolectomy of the left femoral artery and distal vasculature with good establishment of flow.
Admission ECG revealed evidence of a remote anterior myocardial infarction (MI) (Fig 1) and negative cardiac enzyme studies. Absence of pulses in the left radial and right dorsalis pedis arteries prompted arteriograms which revealed evidence of prior emboli to the left axillary and right ilio-femoral artery. Echocardiogram showed anterior and apical akinesis with mural thrombus formation in the left ventricular apex (Fig 2) . He was started on therapy with warfarin and had no further symptoms. There was no other cardiac history or pertinent family, social or past medical history.
Physical examination was within normal limits except for the absence of left radial, right dorsalis pedis and posterior tibial pulses. Chest x-ray film findings were within normal limits.
The patient underwent cardiac catheterization which revealed akinesis of the anterolateral, apical and apical inferior segments of the left ventricle with evidence of mural thrombus present. The left main coronary artery and left circumflex (LCX) were within normal limits with a left dominant system. The left anterior descending (LAD) artery had a serpiginous filling defect proximal to the first septal perforator extending beyond the midpoint of the vessel indicating a linear dissection (Fig 3) . There was no evidence of spasm or atherosclerosis within this vessel. The right coronary artery (RCA) was a small non-dominant normal vessel.
The patient tolerated the procedure well and subsequently has done well on therapy with warfarin, without further embolic events. 
